BLCO News and Press, Bausch + Lomb Corporation From 01/02/26

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that it closed the previously announced credit agreement refinancing. In connec...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice President and Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Re...

2025-12-18 21:04:54 ET This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn’s 13F portfolio on a quarterly basis. It is based on Icahn’s regulatory 13F Form filed on 11/14/2025. Please visit our Tracking Carl Icahn ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Eduardo C. Alfonso, MD, and Steven H. Collis have been appointed to its board of directors. The appointments are effective Jan. 1, 2026, and ...

2025-12-17 09:02:19 ET Recent News On Friday last week, shares of LENZ Therapeutics, Inc. ( LENZ ) fell around 25% after news broke of an “adverse event” from its leading drug, VIZZ. Shares have continued to fall in the aftermath, now down around 30% from T...

2025-12-15 15:33:48 ET Back in September of this year, I made the difficult decision to downgrade Bausch + Lomb ( BLCO ) from a "Buy" to a "Hold." The company looked mostly fairly valued at that moment, and I had been disappointed by some of its bottom-line performance. The firm is ...

2025-12-12 17:18:05 ET More on Bausch + Lomb, Bausch Health Companies Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation Presents at Citi Annual Global Healthcare Conference 2025 Transcript Bausch Health Companies Inc. (BHC) Presents at Evercore 8th Annual Healthcare...

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that it allocated a $2,802,125,000 tranche (the “Replacement Term Loans ...

2025-12-11 14:05:47 ET More on Intuitive Surgical, Penumbra, etc. Intuitive Surgical: Strong Fundamentals, Yet Market Price Reflects Most Of The Opportunity Bausch + Lomb Corporation (BLCO) Bausch + Lomb Corporation Presents at Citi Annual Global Healthcare Conference 2025 T...

2025-12-05 09:33:26 ET More on related stocks: SoFi: $1.5B Dilution Raises Red Flags As Insiders Keep Selling SentinelOne Q3: CFO's Parting Gift To Bulls (Rating Upgrade) Hewlett Packard Enterprise Company 2025 Q4 - Results - Earnings Call Presentation SoFi T...